DZ3320A1 - Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine - Google Patents

Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine

Info

Publication number
DZ3320A1
DZ3320A1 DZ013320A DZ013320A DZ3320A1 DZ 3320 A1 DZ3320 A1 DZ 3320A1 DZ 013320 A DZ013320 A DZ 013320A DZ 013320 A DZ013320 A DZ 013320A DZ 3320 A1 DZ3320 A1 DZ 3320A1
Authority
DZ
Algeria
Prior art keywords
eletriptane
sulphobutylether
migraine
cyclodextrin
complex
Prior art date
Application number
DZ013320A
Other languages
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ3320A1 publication Critical patent/DZ3320A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DZ013320A 1999-06-29 2000-06-02 Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine DZ3320A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (fr) 1999-06-29 2000-06-02 Complexe pharmaceutique

Publications (1)

Publication Number Publication Date
DZ3320A1 true DZ3320A1 (fr) 2001-01-04

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013320A DZ3320A1 (fr) 1999-06-29 2000-06-02 Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine

Country Status (44)

Country Link
US (2) US6713461B1 (fr)
EP (1) EP1189640B1 (fr)
JP (2) JP4454900B2 (fr)
KR (1) KR20020015067A (fr)
CN (1) CN1198654C (fr)
AP (1) AP2001002369A0 (fr)
AR (1) AR033337A1 (fr)
AT (1) ATE290884T1 (fr)
AU (1) AU770169B2 (fr)
BG (1) BG106151A (fr)
BR (1) BR0011845A (fr)
CA (1) CA2376847C (fr)
CO (1) CO5170494A1 (fr)
CZ (1) CZ20014572A3 (fr)
DE (1) DE60018744T2 (fr)
DZ (1) DZ3320A1 (fr)
EA (1) EA003908B1 (fr)
EC (1) ECSP003551A (fr)
EE (1) EE200100697A (fr)
ES (1) ES2235879T3 (fr)
GB (1) GB9915231D0 (fr)
GE (1) GEP20043377B (fr)
GT (1) GT200000102A (fr)
HR (1) HRP20010951A2 (fr)
HU (1) HUP0201629A3 (fr)
IL (1) IL146341A0 (fr)
IS (1) IS6163A (fr)
MA (1) MA26801A1 (fr)
MX (1) MXPA01013274A (fr)
NO (1) NO20016430L (fr)
NZ (1) NZ515235A (fr)
OA (1) OA11964A (fr)
PA (1) PA8496801A1 (fr)
PE (1) PE20010346A1 (fr)
PL (1) PL352902A1 (fr)
SK (1) SK18932001A3 (fr)
SV (1) SV2002000112A (fr)
TN (1) TNSN00142A1 (fr)
TR (1) TR200103827T2 (fr)
UA (1) UA66932C2 (fr)
UY (1) UY26224A1 (fr)
WO (1) WO2001000243A1 (fr)
YU (1) YU87501A (fr)
ZA (1) ZA200110454B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
TWI307626B (en) * 2002-08-20 2009-03-21 Bristol Myers Squibb Co Aripiprazole complex formulation and method
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (fr) * 2016-01-15 2017-07-20 Cadila Healthcare Limited Composition intranasale comprenant des agonistes de récepteur 5ht1b/1d
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
DE9190141U1 (fr) 1990-10-15 1993-07-15 Pfizer, Inc., New York, N.Y., Us
JPH09502698A (ja) 1993-03-05 1997-03-18 ヘクサル・アクチエンゲゼルシャフト 塩酸ラニチジンの結晶シクロデキストリン複合体、その製造方法およびその複合体を含有する薬剤組成物
ZA951877B (en) 1994-03-07 1996-09-09 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
CA2259418A1 (fr) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Composition pharmaceutique contenant un sel d'addition acide d'un medicament de base
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
WO1999001135A1 (fr) 1997-07-03 1999-01-14 Pfizer Limited Compositions pharmaceutiques contenant hemisulfate d'eletriptane et cafeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
BR0011845A (pt) 2002-03-05
AP2001002369A0 (en) 2001-12-31
JP4454900B2 (ja) 2010-04-21
IL146341A0 (en) 2002-07-25
EA003908B1 (ru) 2003-10-30
UY26224A1 (es) 2001-01-31
MA26801A1 (fr) 2004-12-20
JP2006257091A (ja) 2006-09-28
CA2376847C (fr) 2007-09-25
ECSP003551A (es) 2002-01-25
DE60018744T2 (de) 2006-05-18
YU87501A (sh) 2004-05-12
NO20016430L (no) 2002-02-26
HUP0201629A3 (en) 2003-11-28
TNSN00142A1 (fr) 2005-11-10
EE200100697A (et) 2003-02-17
EP1189640A1 (fr) 2002-03-27
KR20020015067A (ko) 2002-02-27
SK18932001A3 (sk) 2002-09-10
CZ20014572A3 (cs) 2002-08-14
AU770169B2 (en) 2004-02-12
ATE290884T1 (de) 2005-04-15
PL352902A1 (en) 2003-09-22
WO2001000243A1 (fr) 2001-01-04
GB9915231D0 (en) 1999-09-01
EA200101106A1 (ru) 2002-06-27
MXPA01013274A (es) 2002-06-04
US6713461B1 (en) 2004-03-30
IS6163A (is) 2001-11-16
GEP20043377B (en) 2004-04-13
NO20016430D0 (no) 2001-12-28
CN1198654C (zh) 2005-04-27
CO5170494A1 (es) 2002-06-27
BG106151A (en) 2002-05-31
ES2235879T3 (es) 2005-07-16
JP2003503364A (ja) 2003-01-28
PE20010346A1 (es) 2001-03-26
US20040186076A1 (en) 2004-09-23
NZ515235A (en) 2003-08-29
HRP20010951A2 (en) 2005-04-30
TR200103827T2 (tr) 2002-05-21
PA8496801A1 (es) 2002-02-21
AR033337A1 (es) 2003-12-17
DE60018744D1 (de) 2005-04-21
CA2376847A1 (fr) 2001-01-04
EP1189640B1 (fr) 2005-03-16
GT200000102A (es) 2001-12-14
CN1359303A (zh) 2002-07-17
AU4774100A (en) 2001-01-31
SV2002000112A (es) 2002-02-05
UA66932C2 (en) 2004-06-15
OA11964A (en) 2006-04-17
ZA200110454B (en) 2002-12-20
HUP0201629A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
FR2785521B1 (fr) Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
PT1028954E (pt) Imidazoles substituidos uteis no tratamento de doencas inflamatorias
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
FR2754713B1 (fr) Utilisation de complexes pour la preparation de compositions pour le traitement des peaux sensibles, procede de preparation et compositions hypoallergeniques
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
MA24332A1 (fr) Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
FR2758465B1 (fr) Composition pour le traitement de l'amiante
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
FR2751544B1 (fr) Composition therapeutique pour le traitement des verrues vulgaires